What question did this study set out to answer?

To determine the biological role of the wild-type KRAS allele in mutant KRAS-driven pancreatic tumorigenesis, disease progression, and response to targeted therapy.

October 16, 2024Cancer ResearchOpen Access

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

View Full Paper

Ask AI

Bookmark

Authors

SFSigrid K. FeyAstraZeneca (United Kingdom)ANArafath K. NajumudeenÅbo Akademi University DWDale M. WattCancer Research UK

Discussion

Member takes

Implication

Preclinical study reveals that wild-type KRAS loss accelerates tumor initiation while enhancing MEK inhibitor sensitivity in mouse models, highlighting KRAS allelic status as a therapeutic guide.

Key Points

To determine the biological role of the wild-type KRAS allele in mutant KRAS-driven pancreatic tumorigenesis, disease progression, and response to targeted therapy.
Utilized in vivo genetically engineered mouse models of pancreatic cancer, including KPC mice, with targeted deletion of the wild-type Kras allele.
Analyzed downstream MAPK effector pathway activation, pancreatic intraepithelial neoplasia initiation, tumor progression rates, and immunogenic gene expression signatures.
Evaluated tumor therapeutic sensitivity and resistance development following pharmacological MEK1/2 inhibition.
Deletion of wild-type Kras elevated downstream oncogenic MAPK signaling, which accelerated the initiation of pancreatic intraepithelial neoplasia.
KPC mice lacking wild-type Kras exhibited accelerated tumor initiation but delayed overall tumor progression, accompanied by altered stroma and enriched immunogenic signatures.
Loss of the wild-type allele sensitized Kras-mutant tumors to MEK1/2 inhibition, although tumors eventually acquired resistance and resumed rapid progression.

Cite This Study

Fey et al. (2024) studied this question.

synapsesocial.com/papers/6aa81c8ff57d08980957492e https://doi.org/10.1158/0008-5472.can-23-2709

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that wild-type KRAS loss accelerates tumor initiation while enhancing MEK inhibitor sensitivity in mouse models, highlighting KRAS allelic status as a therapeutic guide.

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider